卢卡木单抗
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目標 | CD40 |
| 臨床資料 | |
| 其他名稱 | CHIR 12.12、HCD122 |
| ATC碼 |
|
| 识别信息 | |
| CAS号 | 903512-50-5  |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化学信息 | |
| 摩尔质量 | 146 kg/mol |
卢卡木单抗（INN：Lucatumumab；开发代号：CHIR 12.12或HCD122）[1]是一种针对CD40[2]的人单克隆抗体，诺华在研究其用于治疗多发性骨髓瘤和滤泡性淋巴瘤等多种类型的癌症后，于2013年停止了其开发。[3]
它是CD40的拮抗剂，由凯荣公司的科学家使用Abgenix的XenoMouse转基因小鼠产生完全人类抗体而创造。[4][5]该药物的研发成为了凯荣和Xoma公司于2004年开始合作的一部分。[6][7][8]诺华于2005年收购凯荣后接手了该项目。[9][10]
在体外研究中，它抑制CD40配体诱导的细胞增殖并诱导细胞裂解。[11]
在针对多发性骨髓瘤和慢性淋巴细胞白血病的三项1期试验中，这些公司努力确定最佳剂量，但获得了尚不清楚的结果。[1]计划中的多发性骨髓瘤I/II期试验的I期部分于2005年开始，并于2012年更新为II期并结束；截至2014年，结果尚未公布。[1]
参考资料[编辑]
- ^ 1.0 1.1 1.2 Hassan SB, Sørensen JF, Olsen BN, Pedersen AE. Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials. Immunopharmacology and Immunotoxicology. April 2014, 36 (2): 96–104. PMID 24555495. S2CID 21840914. doi:10.3109/08923973.2014.890626.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council – Lucatumumab, American Medical Association.
- ^ Lucatumumab. AdisInsight. [20 February 2017] （英语）.
- ^ Press release: XOMA and Chiron Announce Preclinical Data Presentations on CHIR-12.12 at American Hematology Conference. XOMA and Chiron vis Businesswire. December 2, 2004 （英语）.
- ^ Weng WK, Tong X, Luqman M, Levy R. (Poster Session No. 627-II) A Fully Human Anti-CD40 Antagonistic Antibody, CHIR-12.12, Inhibit the Proliferation of Human B Cell Non-Hodgkin's Lymphoma.. Blood. 16 November 2004, 104 (11): 3279. ISSN 0006-4971. doi:10.1182/blood.V104.11.3279.3279 （英语）.
- ^ Chiron and Xoma in MAb deal - Pharmaceutical industry news. The Pharma Letter. March 8, 2004 （英语）.. Part of Xoma's 10-K filed 2004-03-15. Index page at SEC Edgar.
- ^ Exhibit 10.50: Agreement, dated Feb 27, 2004, by and btwn Chiron Corp and XOMA. Xoma via SEC Edgar.
- ^ Exhibit 10.2 Amended Research, Development and Commercialization Agreement. www.sec.gov. Xoma via SEC Edgar. May 26, 2005.
- ^ Tansey B. Novartis to buy Chiron / Swiss pharmaceutical giant to pay $5.1 billion. San Francisco Chronicle. November 1, 2005.
- ^ Press Release: XOMA Restructures Drug Development Collaboration Including Oncology Drug Candidate HCD122 (NASDAQ:XOMA). Xoma. November 10, 2008 [February 20, 2017]. （原始内容存档于February 20, 2017） （英语）.
- ^ Lucatumumab. NCI Drug Dictionary. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute (NCI). 2011-02-02 [20 February 2017].
| |||||||||||||||||||||||||||||||||||||||